What is Global Rabies Immune Globulin (Human) Market?
The Global Rabies Immune Globulin (Human) Market is a specialized sector of the pharmaceutical industry that focuses on the production and distribution of Rabies Immune Globulin, a human-derived product used in the prevention of rabies. This market is of significant importance due to the critical role Rabies Immune Globulin plays in combating the deadly rabies virus. The product is administered to individuals who have been potentially exposed to the rabies virus, usually through a bite or scratch from an infected animal. It provides immediate, short-term protection by neutralizing the virus and preventing it from spreading within the body. The global market for this product is influenced by various factors, including the prevalence of rabies in different regions, the availability and accessibility of the product, and advancements in production technology. However, the market also faces challenges such as high production costs and stringent regulatory requirements.
HyperRAB S/D, KEDRAB in the Global Rabies Immune Globulin (Human) Market:
HyperRAB S/D and KEDRAB are two key products in the Global Rabies Immune Globulin (Human) Market. HyperRAB S/D, produced by Grifols, and KEDRAB, produced by Kamada, are both human rabies immune globulins used for post-exposure prophylaxis of rabies infection. These products are administered as soon as possible after exposure to the rabies virus, along with a series of rabies vaccinations. They work by providing immediate passive immunity until the body can mount its own immune response through the action of the vaccine. The production and distribution of these products are influenced by various factors, including the incidence of rabies exposure, the effectiveness of the products, and their cost and availability. Despite the challenges, the market for these products continues to grow, driven by the ongoing need for effective rabies post-exposure prophylaxis.
Clinic, Hospital in the Global Rabies Immune Globulin (Human) Market:
The Global Rabies Immune Globulin (Human) Market plays a crucial role in healthcare settings such as clinics and hospitals. In these settings, Rabies Immune Globulin is used as a critical component of post-exposure prophylaxis for individuals potentially exposed to the rabies virus. In clinics, the product is often administered as part of a comprehensive treatment plan that includes wound care, rabies vaccination, and patient education. In hospitals, it is used in emergency departments and other acute care settings to treat patients who have been potentially exposed to rabies. The use of Rabies Immune Globulin in these settings is guided by clinical protocols and guidelines, and its administration is typically overseen by healthcare professionals with specialized training in infectious diseases.
Global Rabies Immune Globulin (Human) Market Outlook:
The future outlook for the Global Rabies Immune Globulin (Human) Market is promising, as indicated by a recent survey. The survey projects that the global market for Rabies Immune Globulin will grow from its current value of US$ 1500 million in 2022 to an estimated US$ 1973.9 million by 2029. This represents a compound annual growth rate (CAGR) of 4.0% during the period from 2023 to 2029. This projected growth is likely to be driven by several factors, including an increase in the incidence of rabies exposure, advancements in product development and manufacturing technology, and increased awareness and accessibility of rabies post-exposure prophylaxis. However, the market also faces potential challenges, including high production costs and stringent regulatory requirements.
| Report Metric | Details |
| Report Name | Rabies Immune Globulin (Human) Market |
| Accounted market size in 2022 | US$ 1500 million |
| Forecasted market size in 2029 | US$ 1973.9 million |
| CAGR | 4.0% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | CSL Behring, Grifols, Sanofi, Kamada, Bharat Serum, Bio Products Laboratory, Shanghai RAAS, Weiguang Bio, Shuanglin Bio, CBPO, CNBG, Sichuan Yuanda Shuyang, Kedrion Biopharma, Congruent Pharmachem, hualanbio |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
